A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

NCT06351904 ↗

Phase 1 Recruiting 72 enrolled Ractigen Therapeutics.

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of RAG-01 in patients with NMIBC who have failed BCG therapy.

Timeline

Start: 2024-04-03
Primary completion: 2028-08-31
Completion: 2028-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RAG-01	Unknown	30 mg	—
Subject	RAG-01	Unknown	100 mg	—
Subject	RAG-01	Unknown	300 mg	—
Subject	RAG-01	Unknown	600 mg	—

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

Summary

Timeline

Drugs

Indications